title: Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
abstract: Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.
authors.affiliation: ICRF Department of Clinical Oncology, UMDS, Guy's Hospital, London.
authors.forename: R D
authors.initials: RD
authors.lastname: Rubens
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
authors.forename: M
authors.initials: M
authors.lastname: Soukop
authors.forename: C J
authors.initials: CJ
authors.lastname: Williams
authors.forename: M H
authors.initials: MH
authors.lastname: Brampton
authors.forename: A L
authors.initials: AL
authors.lastname: Harris
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors
chemical_list: D000964:Antimetabolites, Antineoplastic; D006877:Hydroxamic Acids; D012264:Ribonucleotide Reductases; C035419:3,4-dihydroxybenzohydroxamic acid